|
| 35259016 | Small molecule C381 targets the lysosome to reduce inflammation and ameliorate disease in models of neurodegeneration. | Proc Natl Acad Sci U S A | 2022 |
| 35874767 | Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton's Tyrosine Kinase. | Frontiers in Immunology | 2022 |
| 33454843 | Cannabinoid type 1 receptors in A2a neurons contribute to cocaine-environment association. | Psychopharmacology | 2021 |
| 33540074 | Acute and late administration of colony stimulating factor 1 attenuates chronic cognitive impairment following mild traumatic brain injury in mice. | Brain, Behavior, and Immunity | 2021 |
| 33519915 | LncRNA H19 Suppresses Osteosarcomagenesis by Regulating snoRNAs and DNA Repair Protein Complexes. | Frontiers in Genetics | 2020 |
| 32131714 | Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. | Hematology | 2020 |
| 30517869 | Cooperative Transcription Factor Induction Mediates Hemogenic Reprogramming. | Cell Rep | 2018 |
| 28592889 | Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. | Leukemia | 2018 |
| 30030853 | The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC). | European Journal of Haematology | 2018 |
| 28031181 | Ibrutinib inhibits pre-BCR B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. | Blood | 2017 |
| 28428442 | Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. | Molecular Cancer Therapeutics | 2017 |
| 28363982 | Deficiency in Neuronal TGF-β Signaling Leads to Nigrostriatal Degeneration and Activation of TGF-β Signaling Protects against MPTP Neurotoxicity in Mice. | J Neurosci | 2017 |
| 27904766 | The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. | American Journal of Cancer Research (discontinued) | 2016 |
| 26954547 | Hematopoietic Reprogramming In Vitro Informs In Vivo Identification of Hemogenic Precursors to Definitive Hematopoietic Stem Cells. | Developmental Cell | 2016 |
| 26715645 | Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. | Cancer Discovery | 2016 |
| 26660519 | Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. | Clin Cancer Res | 2016 |
| 26582643 | BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. | Leukemia | 2016 |
| 27678331 | Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth. | Molecular Cancer Therapeutics | 2016 |
| 26193343 | Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. | Nat Med | 2015 |
| 25860607 | Modeling familial cancer with induced pluripotent stem cells. | Cell | 2015 |
| 25730880 | Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. | Proceedings of the National Academy of Sciences of the United States of America | 2015 |
| 26095607 | Tbx3 Controls Dppa3 Levels and Exit from Pluripotency toward Mesoderm. | Stem Cell Reports | 2015 |
| 26529251 | Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. | Journal of Clinical Investigation | 2015 |
| 26487364 | Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo. | Scientific Reports | 2015 |
| 25082755 | Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. | Cancer Discov | 2014 |
| 24316417 | The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. | | 2014 |
| 24311722 | Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). | Blood | 2014 |
| 24332241 | Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. | Lancet Oncology, The | 2014 |
| 24869598 | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. | N Engl J Med | 2014 |
| 24721226 | Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. | Drug Discovery Today | 2014 |
| 25189909 | Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells. | In Vivo | 2014 |
| 24659631 | Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. | Blood | 2014 |
| 23045577 | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. | Journal of Clinical Oncology | 2013 |
| 23770078 | Induction of a hemogenic program in mouse fibroblasts. | Cell Stem Cell | 2013 |
| 23940282 | Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. | Blood | 2013 |
| 23886836 | Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. | Blood | 2013 |
| 23782158 | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. | New England Journal of Medicine | 2013 |
| 23782157 | Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. | N Engl J Med | 2013 |
| 23136880 | Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. | | 2012 |
| 22689860 | Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. | Blood | 2012 |
| 22871175 | Emergency department diagnosis of upper extremity deep venous thrombosis using bedside ultrasonography. | Critical Ultrasound Journal | 2012 |
| 22279054 | The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. | Blood | 2012 |
| 22862944 | Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. | Cell Stem Cell | 2012 |
| 21752263 | The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. | | 2011 |
| 21477851 | Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. | Cell | 2011 |
| 20535210 | Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. | Nature | 2010 |
| 19609559 | Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. | Journal of Cancer Research and Clinical Oncology | 2010 |
| 20615965 | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. | Proceedings of the National Academy of Sciences of the United States of America | 2010 |
| 20145120 | R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. | Cancer Research | 2010 |
| 19596999 | JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. | Journal of Immunology | 2009 |